东诚药业：控股子公司获药物临床试验批准通知书

Core Viewpoint - Dongcheng Pharmaceutical announced that its subsidiary, Lanna, has received approval from the National Medical Products Administration for the clinical trial of the 225Ac-LNC1011 injection, which will commence shortly [1] Group 1: Product Information - The 225Ac-LNC1011 injection is a targeted alpha-particle radiotherapy drug aimed at treating patients with advanced prostate cancer who express PSMA [1] - There are currently no similar products available in the domestic or international markets, nor are there any related sales data [1]